目前和新兴的治疗方法用于血管认知障碍和痴呆症
Louise S Goodall1, Matthew J Lennon2, Perminder S Sachdev3
1Samaras Laboratory, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
Journal of the American College of Cardiology
|January 7, 2026
概括
血管认知障碍和痴呆症 (VCID) 管理落后于阿尔茨海默病. 控制心血管风险因素是预防和治疗VCID的关键,新兴的生物标志物有望提供个性化疗法.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 老年病的医生 老年病的医生
背景情况:
- 心血管风险因素是痴呆的主要原因,血管认知障碍和痴呆症 (VCID) 约占病例的20%.
- 对VCID的治疗进展远远落后于阿尔茨海默病 (AD) 的治疗进展.
研究的目的:
- 审查VCID管理和预防的当前进展和新视角.
- 探索治疗策略和生物标志物在VCID的精密医学中的作用.
主要方法:
- 对VCID的认知增强剂,抗抑郁药和行为干预措施的现有证据的审查.
- 分析主要和次要预防策略,重点关注心血管风险因素管理.
- 讨论新型干预措施和生物标志物的潜在影响.
主要成果:
- 认知增强剂对血管痴呆症 (VaD) 显示出适度的益处,特别是在同时存在的AD病理方面.
- 在VCID中,行为干预是动荡/精神病的第一线治疗;抗精神病药物可能有助于同时患有AD和VCID.
- 管理高血压,糖尿病,吸烟,心房动,肥胖和久坐是预防VCID的关键.
结论:
- 有效的VCID管理需要解决心血管风险,并探索新的治疗途径.
- 生物标志物的发现对于推进精准医学和开发向的VCID疗法至关重要.
相关概念视频
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Dementia
511
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
511
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
544
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
544
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Development During Adulthood
768
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
768
Peripheral Artery Disease III: Interprofessional Care
236
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
236


